Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Shionogi Initiates Rolling NDA Submission in US for Lusutrombopag
September 26, 2017
- Daiichi Sankyo’s Esaxerenone Hits Primary Endpoint in Patients with Essential Hypertension
September 26, 2017
- Medipal/JCR Want to Establish JV by Year End, Go Global with 8 Products
September 25, 2017
- Pfizer to Discontinue 5 Generics, Transition Period Slated until March 2019
September 25, 2017
- Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
- Asahi Kasei Obtains Japan Development Rights for Autologous Cell Therapy Product from Belgium Company
September 25, 2017
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda
September 22, 2017
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US
September 22, 2017
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head
September 22, 2017
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
September 22, 2017
- Japan Oncology Market to Grow Annual 6-9% through 2021: IMS
September 21, 2017
- Opdivo Approved for Non-Squamous NSCLC in Taiwan
September 21, 2017
- Intuniv Hits Primary Endpoint in Adult ADHD: Shionogi/Shire
September 21, 2017
- Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia
September 21, 2017
- hsCRP Levels Will Be Cardiovascular Risk Predictor: Takeda’s Post-Hoc Analysis from EXAMINE Study
September 21, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in HBV Carriers Too: PIII Sub-Analysis
September 20, 2017
- Opdivo Gets Label Expansion for Melanoma in South Korea
September 20, 2017
- NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors
September 20, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Daiichi Sankyo Links Up with MD Anderson on AML Therapies
September 19, 2017
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…